Combination of organic compounds
OwnerRobert Edson Damon, Thomas Edward Hughesinventors
Life of this patent
Estimating the term…
Abstract
The present invention relates to a combination, especially a pharmaceutical composition, comprising as active ingredients (i) a HMG-CoA reductase inhibitor or a or a pharmaceutically acceptable salt thereof; (ii) (a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof or (b) an insulin sensitizer or a pharmaceutically acceptable salt thereof; and, in case of a pharmaceutical composition, a pharmaceutically acceptable carrier.
Claims17
A combination of at least two components selected from the group consisting of:
- (i) a HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, and
- (ii) a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof, or
- b) an insulin sensitizer or a pharmaceutically acceptable salt thereof.
A combination of at least two components selected from the group consisting of:
- (i) a HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and
- (ii) a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof, selected from the group consisting of :tolbutamide;
- chlorpropamide;
- tolazamide;
- acetohexamide;
- glycopyramide;
- glibenclamide;
- gliclazide;
- 1-butyl-3-metanilylurea;
- carbutamide;
- glibonuride;
- glipizide;
- gliquidone;
- glisoxepid;
- glybuthiazole;
- glibuzole;
- glyhexamide;
- glymidine;
- glypinamide;
- phenbutamide;
- tolylcyclamide, nateglinide, repaglinide, mitiglinide, glimepiride, a DPP-IV inhibitor, GLP1, GLP-1(7-36);Gln.sup.9-GLP-1(7-37);
- D -Gln.sup.9-GLP-1(7-37);
- acetyl-Lys.sup.9-GLP-1(7-37);
- Thr.sup.16-Lys.sup.18-GLP-1(7-37);
- and Lys.sup.18-GLP-1(7-37) or
- b) an insulin sensitizer or a pharmaceutically acceptable salt thereof.
A method for the prevention, delay of progression or treatment of a disease and disorder which may be inhibited by the inhibition of HMG-Co-A reductase and/or by the enhancement of insulin secretion comprising administering to a warm-blooded animal, including man, in need thereof jointly therapeutically effective amounts of the composition comprising at least two therapeutic components selected from the group consisting of:
- (i) a HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, selected from the group consisting of atorvastatin, cerivastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, and simvastatin, and
- (ii) a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof, or
- b) an insulin sensitizer or a pharmaceutically acceptable salt thereof.
A method for the prevention, delay of progression or treatment of a disease and disorder which may be inhibited by the inhibition of HMG-Co-A reductase and/or by the enhancement of insulin secretion comprising administering to a warm-blooded animal, including man, in need thereof jointly therapeutically effective amounts of the composition comprising at least two therapeutic components selected from the group consisting of:
- (i) a HMG CoA reductase inhibitor or a pharmaceutically acceptable salt thereof, and
- (ii) a) an insulin secretion enhancer or a pharmaceutically acceptable salt thereof, selected from the group consisting of:
- tolbutamide;
- chlorpropamide;
- tolazamide;
- acetohexamide;
- glycopyramide;
- glibenclamide;
- gliclazide;
- 1-butyl-3-metanilylurea;
- carbutamide;
- glibonuride;
- glipizide;
- gliquidone;
- glisoxepid;
- glybuthiazole;
- glibuzole;
- glyhexamide;
- glymidine;
- glypinamide;
- phenbutamide;
- tolylcyclamide, nateglinide, repaglinide, mitiglinide, glimepiride, a DPP-IV inhibitor, GLP1, GLP-1(7-36);Gln.sup.9-GLP-1(7-37);
- D -Gln.sup.9-GLP-1(7-37);
- acetyl-Lys.sup.9-GLP-1(7-37);
- Thr.sup.16-Lys.sup.18-GLP-1(7-37);
- and Lys.sup.18-GLP-1(7-37) or
- b) an insulin sensitizer or a pharmaceutically acceptable salt thereof.
Dependencies are inferred from the claim text.